Size and oxidative susceptibility of low-density lipoprotein particles in breast cancer patients with tamoxifen-induced fatty liver.
The purpose of the present study was to investigate the effects of tamoxifen on the size and oxidative susceptibility of low-density lipoprotein (LDL) particles in breast cancer patients with tamoxifen-induced fatty liver. We investigated the following breast cancer patients: 13 receiving no tamoxifen (group A), 13 receiving tamoxifen 40 mg daily but without fatty liver (group B), and 13 receiving tamoxifen 40 mg daily with fatty liver (group C). Plasma lipids and diameter of LDL particles were measured. Susceptibility of LDL to oxidation was analyzed by incubation with CuSO(4) while monitoring conjugated diene formation and assaying thiobarbituric acid reactive substances (TBARS). Plasma total and LDL cholesterol concentrations in groups B and C were significantly lower than those in group A. In group C, concentrations of plasma triglyceride (TG) and TBARS were significantly greater, but LDL particle diameter and lag time for LDL oxidation were significantly smaller than those in groups A and B. Plasma TG concentrations correlated negatively with computed tomography ratio of liver to spleen (r = -0.76; P < 0.001). LDL particle diameter correlated negatively with plasma TG (r = -0.62; P < 0.001) and TBARS (r = -0.44; P < 0.01), but positively with LDL lag time (r = 0.47; P < 0.01). Tamoxifen-induced fatty liver in breast cancer patients may be atherogenic, via increased TG and consequent small, easily oxidized LDL particles.
Wakatsuki
Akihiko
A
Department of Obstetrics and Gynecology, Kochi Medical School, Kochi 783-8505, Japan. wakatuki@kochi-ms.ac.jp
Ogawa
Yasuhiro
Y
Saibara
Toshiji
T
Okatani
Yuji
Y
Fukaya
Takao
T
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001786:Blood Glucose; D001943:Breast Neoplasms / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood; D005234:Fatty Liver / Q000097:blood / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects; D010316:Particle Size; D013629:Tamoxifen / Q000009:adverse effects*; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
D018931:Antineoplastic Agents, Hormonal; D001786:Blood Glucose; D007328:Insulin; D008077:Lipoproteins, LDL; D017392:Thiobarbituric Acid Reactive Substances; D014280:Triglycerides; D013629:Tamoxifen; D002784:Cholesterol